FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2601472578> ?p ?o ?g. }

• W2601472578 endingPage "660.e1" @default.
• W2601472578 startingPage "652" @default.
• W2601472578 abstract "Background Clinical data from patients with non–clear cell renal cell carcinoma (nccRCC) receiving targeted therapy are limited, and many clinical trials have excluded these patients from study entry. We sought to investigate the outcomes of patients with nccRCC treated in clinical trials in the modern era compared with the outcomes of patients with clear cell RCC (ccRCC). Patients and Methods We conducted a retrospective study of patients with metastatic RCC who had received targeted therapy in Pfizer-sponsored phase II and III clinical trials from 2003 to 2013. Associations between the histologic type and treatment outcome (overall survival [OS] and progression-free survival [PFS]) were assessed using the log-rank test on univariate analysis or the Wald χ2 test from Cox regression on multivariable analysis, adjusted for baseline characteristics, including age, sex, Eastern Cooperative Oncology Group performance status, body mass index, International Metastatic RCC Database Consortium risk factors, previous nephrectomy, previous therapy, metastatic sites, angiotensin system inhibitor use, and statin use. Results We identified 4527 patients with metastatic RCC: 4235 with ccRCC and 337 with nccRCC. Overall, the median OS was shorter for those with nccRCC than for those with ccRCC (15.7 vs. 20.2 months; hazard ratio [HR], 1.41; 95% confidence interval 1.22-1.63; P < .001). When stratified by the International Metastatic RCC Database Consortium risk group, the median OS was inferior for the intermediate- and poor-risk patients with nccRCC than for those with ccRCC. However, no differences were found in the favorable risk group for nccRCC versus ccRCC. The patients with nccRCC who had received vascular endothelial growth factor-targeted therapy had shorter PFS compared with that of ccRCC patients (median, 6.1 vs. 8.5 months; HR, 1.49; P < .001) but similar PFS when treated with mammalian target of rapamycin inhibitors (median, 4.3 vs. 4.4 months; HR, 0.92; P = .63). Conclusion Our findings have confirmed that patients with nccRCC are underrepresented in clinical trials and highlight the need for further prospective studies exploring current and novel agents for this patient population." @default.
• W2601472578 created "2017-04-07" @default.
• W2601472578 creator A5027485998 @default.
• W2601472578 creator A5052504518 @default.
• W2601472578 creator A5057091501 @default.
• W2601472578 creator A5058325420 @default.
• W2601472578 creator A5060911926 @default.
• W2601472578 creator A5071903899 @default.
• W2601472578 date "2017-12-01" @default.
• W2601472578 modified "2023-10-15" @default.
• W2601472578 title "Comprehensive Analysis of Survival Outcomes in Non–Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials" @default.
• W2601472578 cites W1544119899 @default.
• W2601472578 cites W1583423320 @default.
• W2601472578 cites W1931162541 @default.
• W2601472578 cites W1949140443 @default.
• W2601472578 cites W1965046203 @default.
• W2601472578 cites W1971358860 @default.
• W2601472578 cites W1975807698 @default.
• W2601472578 cites W2010991736 @default.
• W2601472578 cites W2022914202 @default.
• W2601472578 cites W2023952988 @default.
• W2601472578 cites W2040143310 @default.
• W2601472578 cites W2063698832 @default.
• W2601472578 cites W2081372483 @default.
• W2601472578 cites W2103506609 @default.
• W2601472578 cites W2103689170 @default.
• W2601472578 cites W2111867681 @default.
• W2601472578 cites W2115125611 @default.
• W2601472578 cites W2116095691 @default.
• W2601472578 cites W2136110110 @default.
• W2601472578 cites W2138129102 @default.
• W2601472578 cites W2147382551 @default.
• W2601472578 cites W2149456801 @default.
• W2601472578 cites W2153867442 @default.
• W2601472578 cites W2155319477 @default.
• W2601472578 cites W2155771281 @default.
• W2601472578 cites W2156408558 @default.
• W2601472578 cites W2161130083 @default.
• W2601472578 cites W2163207509 @default.
• W2601472578 cites W2173523195 @default.
• W2601472578 cites W2222086386 @default.
• W2601472578 cites W2233483325 @default.
• W2601472578 cites W2233818050 @default.
• W2601472578 cites W2237254160 @default.
• W2601472578 cites W2270637060 @default.
• W2601472578 cites W2284518822 @default.
• W2601472578 cites W2284962658 @default.
• W2601472578 cites W2288944226 @default.
• W2601472578 cites W2335012284 @default.
• W2601472578 cites W2816965188 @default.
• W2601472578 doi "https://doi.org/10.1016/j.clgc.2017.03.004" @default.
• W2601472578 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28410911" @default.
• W2601472578 hasPublicationYear "2017" @default.
• W2601472578 type Work @default.
• W2601472578 sameAs 2601472578 @default.
• W2601472578 citedByCount "31" @default.
• W2601472578 countsByYear W26014725782017 @default.
• W2601472578 countsByYear W26014725782018 @default.
• W2601472578 countsByYear W26014725782019 @default.
• W2601472578 countsByYear W26014725782020 @default.
• W2601472578 countsByYear W26014725782021 @default.
• W2601472578 countsByYear W26014725782022 @default.
• W2601472578 countsByYear W26014725782023 @default.
• W2601472578 crossrefType "journal-article" @default.
• W2601472578 hasAuthorship W2601472578A5027485998 @default.
• W2601472578 hasAuthorship W2601472578A5052504518 @default.
• W2601472578 hasAuthorship W2601472578A5057091501 @default.
• W2601472578 hasAuthorship W2601472578A5058325420 @default.
• W2601472578 hasAuthorship W2601472578A5060911926 @default.
• W2601472578 hasAuthorship W2601472578A5071903899 @default.
• W2601472578 hasConcept C126322002 @default.
• W2601472578 hasConcept C143998085 @default.
• W2601472578 hasConcept C144301174 @default.
• W2601472578 hasConcept C167135981 @default.
• W2601472578 hasConcept C207103383 @default.
• W2601472578 hasConcept C2777472916 @default.
• W2601472578 hasConcept C2781068499 @default.
• W2601472578 hasConcept C2781278892 @default.
• W2601472578 hasConcept C38180746 @default.
• W2601472578 hasConcept C44249647 @default.
• W2601472578 hasConcept C50382708 @default.
• W2601472578 hasConcept C535046627 @default.
• W2601472578 hasConcept C71924100 @default.
• W2601472578 hasConceptScore W2601472578C126322002 @default.
• W2601472578 hasConceptScore W2601472578C143998085 @default.
• W2601472578 hasConceptScore W2601472578C144301174 @default.
• W2601472578 hasConceptScore W2601472578C167135981 @default.
• W2601472578 hasConceptScore W2601472578C207103383 @default.
• W2601472578 hasConceptScore W2601472578C2777472916 @default.
• W2601472578 hasConceptScore W2601472578C2781068499 @default.
• W2601472578 hasConceptScore W2601472578C2781278892 @default.
• W2601472578 hasConceptScore W2601472578C38180746 @default.
• W2601472578 hasConceptScore W2601472578C44249647 @default.
• W2601472578 hasConceptScore W2601472578C50382708 @default.
• W2601472578 hasConceptScore W2601472578C535046627 @default.
• W2601472578 hasConceptScore W2601472578C71924100 @default.
• W2601472578 hasIssue "6" @default.
• W2601472578 hasLocation W26014725781 @default.

• next